PFS
NTLA icon

Prospera Financial Services’s Intellia Therapeutics NTLA Stock Holding History

Prospera Financial Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-351
Closed -$18K – 1351
2022
Q2 		$18K Sell
351
-94
-21% -$4.77K ﹤0.01% 1229
2022
Q1 		$32K Buy
+445
New +$37.7K ﹤0.01% 1553

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prospera Financial Services's NTLA Position: Q3 2022 in Review

Prospera Financial Services sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 351 shares — an estimated $18K sold.

Prospera Financial Services first reported a position in NTLA in Q1 2022 and held it in 2 quarters. The position peaked at $32K in Q1 2022. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

  • Prospera Financial Services reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prospera Financial Services sold 351 Intellia Therapeutics shares in Q3 2022, an estimated $18K.
  • Prospera Financial Services first reported a position in Intellia Therapeutics in Q1 2022 and held it in 2 quarters.
  • Prospera Financial Services's Intellia Therapeutics position peaked at $32K in Q1 2022.
  • 319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Prospera Financial Services's 13F filing for Q3 2022, filed 27 Oct 2022.